Stay updated on MT-5111 in HER2+ Solid Tumors Clinical Trial
Sign up to get notified when there's something new on the MT-5111 in HER2+ Solid Tumors Clinical Trial page.

Latest updates to the MT-5111 in HER2+ Solid Tumors Clinical Trial page
- CheckyesterdayNo Change Detected
- Check9 days agoNo Change Detected
- Check16 days agoChange DetectedThe web page has been updated from version 2.15.0 to version 2.15.2, indicating a revision in the content.SummaryDifference0.1%
- Check23 days agoNo Change Detected
- Check31 days agoChange DetectedThe page has been updated to reflect a new version (v2.15.0) and the addition of the term 'HER2-positive Solid Cancers' and 'MT-5111_001', while significant details about the study's design and eligibility criteria have been removed.SummaryDifference27%
- Check38 days agoChange DetectedThe web page has been updated from version 2.14.3 to version 2.14.4.SummaryDifference0.1%
- Check45 days agoChange DetectedThe web page has been updated from version 2.14.2 to version 2.14.3.SummaryDifference0.1%
- Check81 days agoChange DetectedThe page has removed a notice regarding heavy traffic affecting the performance and availability of some NLM-NCBI services and products.SummaryDifference1%
- Check96 days agoChange DetectedThe web page now includes a notice about heavy traffic affecting the performance and availability of some NLM-NCBI services and products, along with contact information for assistance.SummaryDifference1%
Stay in the know with updates to MT-5111 in HER2+ Solid Tumors Clinical Trial
Enter your email address, and we'll notify you when there's something new on the MT-5111 in HER2+ Solid Tumors Clinical Trial page.